Expand and standardize population-wide evaluation and surveillance data sources and activities to assure adequate assessment of CVD indicators and change in the nation’s CVD burden. Examples include mortality, incidence, prevalence, disability, selected biomarkers, risk factors and risk behaviors, economic burden, community and environmental characteristics, current policies and programs, and sociodemographic factors (e.g., age, race/ethnicity, sex, and ZIP code).
Establish a network of data systems for evaluation of policy and program interventions that can track the progress of evolving best practices and signal the need for changes in policies and programs over time. This network would support the full development, collection, and analysis of the data needed to examine program effectiveness.
Develop the public health infrastructure, build personnel competencies, and enhance communication systems so that federal, state, and local public health agencies can communicate surveillance and evaluation results in a timely and effective manner.
Conduct and facilitate research by means of collaboration among interested parties to identify new policy, environmental, and sociocultural priorities for CVH promotion. Once the priorities are identified, determine the best methods for translating, disseminating, and sustaining them. Fund research to identify barriers and effective interventions in order to translate science into practice and thereby improve access to and use of quality health care and improve outcomes for patients with or at risk for CVD. Conduct economics research, including cost-effectiveness studies and comprehensive economic models that assess the return on investment for CVH promotion as well as primary and secondary CVD prevention.
Design, plan, implement, and evaluate a comprehensive intervention for children and youth in school, family, and community settings. This intervention must address dietary imbalances, physical inactivity, tobacco use, and other determinants in order to prevent development of risk factors and progression of atherosclerosis and high blood pressure.